{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:00:45Z","timestamp":1789012845725,"version":"build-2803163510"},"reference-count":49,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T00:00:00Z","timestamp":1653955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"2020 Moffitt Cancer Center Team Science Award","award":["P30CA076292"],"award-info":[{"award-number":["P30CA076292"]}]},{"name":"Moffitt Cancer Center\u2019s Participant Research, Interventions, and Measurement (PRISM)","award":["P30CA076292"],"award-info":[{"award-number":["P30CA076292"]}]},{"name":"Biostatistics and Bioinformatics Shared Resource (BBSR)","award":["P30CA076292"],"award-info":[{"award-number":["P30CA076292"]}]},{"DOI":"10.13039\/100000054","name":"NIH\/NCI Cancer Center","doi-asserted-by":"publisher","award":["P30CA076292"],"award-info":[{"award-number":["P30CA076292"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Clinicians must closely monitor patients for toxicities after chimeric antigen receptor T-cell therapy (CAR-T). Patient-reported outcomes (PROs) (e.g., toxicities, quality of life) and activity data (e.g., steps, sleep) may complement clinicians\u2019 observations. This study tested the feasibility and acceptability of collecting PROs and activity data from patients with hematologic malignancies during CAR-T and explored preliminary data patterns. Methods: Participants wore a Fitbit tracker and completed PROs at several timepoints through 90-days post-infusion. Feasibility was assessed with a priori benchmarks for recruitment (\u226550%), retention (\u226570%), PRO completion (\u226570%), and days wearing the Fitbit (\u226550%). Acceptability was assessed with participant satisfaction (a priori benchmark &gt; 2 on a 0\u20134 scale). Results: Participants (N = 12) were M = 66 years old (SD = 7). Rates of recruitment (68%), retention (83%), PRO completion (85%), and days wearing the Fitbit (85%) indicated feasibility. Satisfaction with completing the PROs (M = 3.2, SD = 0.5) and wearing the Fitbit (M = 2.9, SD = 0.5) indicated acceptability. Preliminary data patterns suggested that participants with better treatment response (vs. progressive disease) had a higher toxicity burden. Conclusions: Longitudinal PRO and activity data collection was feasible and acceptable. Data collected on a larger scale may be used to specify risk prediction models to identify predictors of severe CAR-T-related toxicities and inform early interventions.<\/jats:p>","DOI":"10.3390\/cancers14112742","type":"journal-article","created":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T03:33:18Z","timestamp":1654054398000},"page":"2742","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Longitudinal Collection of Patient-Reported Outcomes and Activity Data during CAR-T Therapy: Feasibility, Acceptability, and Data Visualization"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6281-2512","authenticated-orcid":false,"given":"Laura B.","family":"Oswald","sequence":"first","affiliation":[{"name":"Department of Health Outcomes and Behavior, Moffitt Cancer Center, 12902 USF Magnolia Dive, MFC-HOB, Tampa, FL 33612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8028-8910","authenticated-orcid":false,"given":"Xiaoyin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Health Outcomes and Behavior, Moffitt Cancer Center, 12902 USF Magnolia Dive, MFC-HOB, Tampa, FL 33612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7607-8272","authenticated-orcid":false,"given":"Rodrigo","family":"Carvajal","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL 33612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8691-8132","authenticated-orcid":false,"given":"Aasha I.","family":"Hoogland","sequence":"additional","affiliation":[{"name":"Department of Health Outcomes and Behavior, Moffitt Cancer Center, 12902 USF Magnolia Dive, MFC-HOB, Tampa, FL 33612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Gudenkauf","sequence":"additional","affiliation":[{"name":"Department of Health Outcomes and Behavior, Moffitt Cancer Center, 12902 USF Magnolia Dive, MFC-HOB, Tampa, FL 33612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris K.","family":"Hansen","sequence":"additional","affiliation":[{"name":"Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL 33612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Alsina","sequence":"additional","affiliation":[{"name":"Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL 33612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick L.","family":"Locke","sequence":"additional","affiliation":[{"name":"Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL 33612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvelise","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Department of Health Outcomes and Behavior, Moffitt Cancer Center, 12902 USF Magnolia Dive, MFC-HOB, Tampa, FL 33612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaly","family":"Irizarry-Arroyo","sequence":"additional","affiliation":[{"name":"Department of Health Outcomes and Behavior, Moffitt Cancer Center, 12902 USF Magnolia Dive, MFC-HOB, Tampa, FL 33612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9625-6235","authenticated-orcid":false,"given":"Edmondo J.","family":"Robinson","sequence":"additional","affiliation":[{"name":"Center for Digital Health, Moffitt Cancer Center, Tampa, FL 33612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7353-3711","authenticated-orcid":false,"given":"Heather S. L.","family":"Jim","sequence":"additional","affiliation":[{"name":"Department of Health Outcomes and Behavior, Moffitt Cancer Center, 12902 USF Magnolia Dive, MFC-HOB, Tampa, FL 33612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5108-5735","authenticated-orcid":false,"given":"Brian D.","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"Department of Health Outcomes and Behavior, Moffitt Cancer Center, 12902 USF Magnolia Dive, MFC-HOB, Tampa, FL 33612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1302-9577","authenticated-orcid":false,"given":"Kedar","family":"Kirtane","sequence":"additional","affiliation":[{"name":"Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","volume":"386","author":"Locke","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJMc2030164","article-title":"Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy","volume":"384","author":"Chong","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.tmrv.2019.01.005","article-title":"Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis","volume":"33","author":"Grigor","year":"2019","journal-title":"Transfus. Med. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_11","first-page":"188","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Tr."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1007\/s00520-016-3297-9","article-title":"The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): A systematic review","volume":"24","author":"Atkinson","year":"2016","journal-title":"Support Care Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1200\/JCO.2014.57.9334","article-title":"Symptomatic toxicities experienced during anticancer treatment: Agreement between patient and physician reporting in three randomized trials","volume":"33","author":"Gallo","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1200\/JCO.2015.63.0830","article-title":"Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial","volume":"34","author":"Basch","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jama.2017.7156","article-title":"Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment","volume":"318","author":"Basch","year":"2017","journal-title":"JAMA"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.jtho.2019.02.005","article-title":"Cost-Effectiveness of Web-Based Patient-Reported Outcome Surveillance in Patients With Lung Cancer","volume":"14","author":"Lizee","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/CCI.17.00147","article-title":"Use of Wearable, Mobile, and Sensor Technology in Cancer Clinical Trials","volume":"2","author":"Cox","year":"2018","journal-title":"JCO Clin. Cancer Inform."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41746-021-00418-3","article-title":"The emerging clinical role of wearables: Factors for successful implementation in healthcare","volume":"4","author":"Smuck","year":"2021","journal-title":"NPJ Digit. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/CCI.17.00149","article-title":"The HOPE Pilot Study: Harnessing Patient-Reported Outcomes and Biometric Data to Enhance Cancer Care","volume":"2","author":"Wright","year":"2018","journal-title":"JCO Clin. Cancer Inform."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/nur.20247","article-title":"Considerations in determining sample size for pilot studies","volume":"31","author":"Hertzog","year":"2008","journal-title":"Res. Nurs. Health"},{"key":"ref_22","first-page":"142","article-title":"Research electronic data capture (REDCap)","volume":"106","author":"Patridge","year":"2018","journal-title":"J. Med. Libr. Assoc. JMLA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1016\/j.bbmt.2018.11.025","article-title":"Patient-Reported Outcomes with Chimeric Antigen Receptor T Cell Therapy: Challenges and Opportunities","volume":"25","author":"Chakraborty","year":"2019","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","article-title":"Validation of a combined comorbidity index","volume":"47","author":"Charlson","year":"1994","journal-title":"J. Clin. Epidemiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.4049\/jimmunol.2001249","article-title":"Biomarkers for Predicting Cytokine Release Syndrome following CD19-Targeted CAR T Cell Therapy","volume":"206","author":"Tedesco","year":"2021","journal-title":"J. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.amepre.2009.02.002","article-title":"How We Design Feasibility Studies","volume":"36","author":"Bowen","year":"2009","journal-title":"Am. J. Prev. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1159\/000501433","article-title":"Feasibility and Usability Aspects of Continuous Remote Monitoring of Health Status in Palliative Cancer Patients Using Wearables","volume":"98","author":"Pavic","year":"2019","journal-title":"Oncology"},{"key":"ref_28","first-page":"8","article-title":"Brief report of a tablet-delivered psychosocial intervention for men with advanced prostate cancer: Acceptability and efficacy by race","volume":"9","author":"Bouchard","year":"2018","journal-title":"Transl. Behav. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/pon.5281","article-title":"Brief culturally informed smartphone interventions decrease breast cancer symptom burden among Latina breast cancer survivors","volume":"29","author":"Yanez","year":"2020","journal-title":"Psychooncology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","article-title":"The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure","volume":"11","author":"Cella","year":"1993","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1089\/jayao.2014.0007","article-title":"Fertility Preservation Preferences and Perspectives Among Adult Male Survivors of Pediatric Cancer and Their Parents","volume":"3","author":"Stein","year":"2014","journal-title":"J. Adolesc. Young Adul."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/01.mlr.0000258615.42478.55","article-title":"The Patient-Reported Outcomes Measurement Information System (PROMIS): Progress of an NIH Roadmap cooperative group during its first two years","volume":"45","author":"Cella","year":"2007","journal-title":"Med. Care"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1007\/s11136-018-1842-3","article-title":"PROMISA (R)-29 v2.0 profile physical and mental health summary scores","volume":"27","author":"Hays","year":"2018","journal-title":"Qual. Life Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1093\/annonc\/mds539","article-title":"The FACT-G7: A rapid version of the functional assessment of cancer therapy-general (FACT-G) for monitoring symptoms and concerns in oncology practice and research","volume":"24","author":"Yanez","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"dju244","DOI":"10.1093\/jnci\/dju244","article-title":"Development of the National Cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)","volume":"106","author":"Basch","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/jamaoncol.2015.2639","article-title":"Validity and reliability of the US National Cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)","volume":"1","author":"Dueck","year":"2015","journal-title":"JAMA Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1177\/1740774520975120","article-title":"Composite grading algorithm for the National Cancer Institute\u2019s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)","volume":"18","author":"Basch","year":"2021","journal-title":"Clin. Trials"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1093\/jnci\/djaa028","article-title":"Evaluating Treatment Tolerability in Cancer Clinical Trials Using the Toxicity Index","volume":"112","author":"Gresham","year":"2020","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4645","DOI":"10.1158\/1078-0432.CCR-03-0535","article-title":"Patient characteristics compete with dose as predictors of acute treatment toxicity in early phase clinical trials","volume":"10","author":"Rogatko","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0005-7967(02)00023-2","article-title":"Quantitative criteria for insomnia","volume":"41","author":"Lichstein","year":"2003","journal-title":"Behav. Res. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1200\/CCI.21.00023","article-title":"Next-Generation Implementation of Chimeric Antigen Receptor T-Cell Therapy Using Digital Health","volume":"5","author":"Banerjee","year":"2021","journal-title":"JCO Clin. Cancer Inform."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e002056","DOI":"10.1136\/jitc-2020-002056","article-title":"Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia","volume":"9","author":"Myers","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1016\/S1470-2045(20)30021-8","article-title":"The increasing value of eHealth in the delivery of patient-centred cancer care","volume":"21","author":"Penedo","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/cpt.1674","article-title":"CAR T-Cell Therapy in Hematologic Malignancies: A Voyage in Progress","volume":"107","author":"Holstein","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e18541","DOI":"10.1200\/JCO.2021.39.15_suppl.e18541","article-title":"Disparities in the use of checkpoint inhibitors and CAR T-cell therapy: A systematic review","volume":"39","author":"Jutagir","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s13187-021-02031-0","article-title":"Project ECHO Cancer Initiative: A Tool to Improve Care and Increase Capacity along the Continuum of Cancer Care","volume":"36","author":"Varon","year":"2021","journal-title":"J. Cancer Educ."},{"key":"ref_47","unstructured":"Arora, S., and Hawk, E. (2017). Ensuring Equitable Cancer Care for All Patients, Available online: https:\/\/ascopost.com\/issues\/may-10-2017\/ensuring-equitable-cancer-care-for-all-patients\/."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e002303","DOI":"10.1136\/jitc-2020-002303","article-title":"Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma","volume":"9","author":"Brammer","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.3389\/fonc.2019.01237","article-title":"Understanding the Mechanisms of Resistance to CAR T-Cell Therapy in Malignancies","volume":"9","author":"Cheng","year":"2019","journal-title":"Front. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/11\/2742\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:23:06Z","timestamp":1760138586000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/11\/2742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,31]]},"references-count":49,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["cancers14112742"],"URL":"https:\/\/doi.org\/10.3390\/cancers14112742","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,31]]}}}